Bloomberg -- Novartis AG is stopping development of two experimental medicines, a decision that will result in charges of about $590 million in charges in the third quarter.
Bloomberg -- Novartis AG is stopping development of two experimental medicines, a decision that will result in charges of about $590 million in charges in the third quarter.
